Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2018
At a glance
- Drugs GS 010 (Primary)
- Indications Leber's hereditary optic atrophy
- Focus Registrational; Therapeutic Use
- Acronyms REFLECT
- Sponsors GenSight Biologics
- 05 Apr 2018 Status changed from not yet recruiting to recruiting.
- 03 Apr 2018 According to a GenSight Biologics media release, first patient in this study was treated in Mar 2018.
- 15 Jan 2018 Planned initiation date changed from 30 Dec 2017 to 28 Feb 2018.